What is the current market size?

The Celecoxib market size reached USD 1.2 billion in 2023, driven by rising arthritis prevalence and demand for safer NSAIDs.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, bolstered by chronic disease management trends.

What are the key growth drivers?

Key drivers include aging populations, rising osteoarthritis cases, and increased adoption of COX-2 inhibitors over traditional NSAIDs.

What challenges does the market face?

Challenges include patent expirations, generic competition, and regulatory scrutiny over cardiovascular risks.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth from expanding patient pools.

Who are the top manufacturers?

Leading companies include Johnson & Johnson, Pfizer, and Takeda Pharmaceutical, leveraging established brands and R&D pipelines.

What future opportunities exist?

Opportunities lie in emerging economies, drug combination therapies, and innovation in pediatric and geriatric formulations.

How does technology influence the market?

Advancements in biopharmaceuticals and personalized medicine enhance Celecoxib's efficacy and safety profiles, driving adoption.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA enforce strict safety guidelines, impacting approval timelines and post-market monitoring requirements.

Are there recent developments?

Recent trends include biosimilar launches, expanded labeling for chronic pain, and clinical trials on long-term safety improvements.

Celecoxib Value Chain Analysis & Forecast Outlook 2033

Celecoxib by Application (Rheumatoid arthritis, osteoarthritis, Acute pain, Musculoskeletal pain, Other diseases), by Types (50mg, 100mg, 200mg, 400mg), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Celecoxib Market Overview

Celecoxib, a selective COX-2 inhibitor, is a key pharmaceutical agent prescribed for managing pain and inflammation in conditions like arthritis. Its relevance in the global healthcare landscape is underscored by its efficacy in mitigating chronic pain with reduced gastrointestinal side effects compared to traditional NSAIDs. The Celecoxib market size is projected to reflect robust industry expansion, driven by rising chronic disease prevalence and evolving treatment paradigms. According to recent estimates, the market was valued at USD 1.2 billion in 2023, with a growth outlook indicating a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033. This trajectory is underpinned by macro drivers such as aging demographics, increased geriatric arthritis cases, and regulatory tailwinds supporting generic drug approvals.

Loading chart…

Two pivotal forces shaping the Celecoxib market forecast are technological advancements in drug delivery systems and the erosion of patent protections for branded formulations, intensifying competitive intensity. The U.S. remains the largest regional market, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and rising patient awareness. Strategic partnerships between generic manufacturers and pharmaceutical distributors are further accelerating market expansion, albeit amid challenges like biosimilar competition and pricing pressures. By 2033, the market is poised to reflect a balanced shift toward cost-effective therapies, with rheumatoid arthritis applications retaining a dominant share in the therapeutic pipeline.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.71 billion
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Teva; Mylan; Apotex; Lupin; Hengrui Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Celecoxib market is poised for expansion due to its established role in managing chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis, driven by an aging global population. Rising prevalence of these conditions, particularly in North America and Europe, underscores long-term demand stability.

Strategic partnerships between pharmaceutical firms and biotech innovators are accelerating the development of combination therapies involving Celecoxib, enhancing its therapeutic efficacy. This aligns with the growth forecast for 2024–2030, as payers and providers prioritize cost-effective solutions with improved patient adherence.

Restraints2 items

Stringent regulatory scrutiny from the FDA and EMA, particularly regarding cardiovascular risks, is dampening market accessibility. Post-marketing surveillance requirements may delay approvals in emerging markets, limiting the Celecoxib market size expansion in Asia-Pacific and Latin America.

The availability of low-cost generic NSAIDs, such as diclofenac and naproxen, is intensifying price competition. This pressures branded Celecoxib players to differentiate through value-added services, despite the drug’s niche COX-2 inhibition mechanism.

Opportunities2 items

Biomarker-based patient stratification is unlocking new applications for Celecoxib in precision oncology, particularly for colorectal cancer prevention. This niche positioning could drive premium pricing and expand the Celecoxib market beyond traditional indications.

Emerging markets present untapped potential due to improving healthcare infrastructure and rising awareness of advanced pain management solutions. Localized formulations tailored to regional disease profiles may capture underserved patient segments.

Challenges2 items

Safety concerns over long-term cardiovascular side effects continue to influence prescribing patterns, with gastroenterologists and rheumatologists favoring alternatives in high-risk patient cohorts. This perception risks eroding market share despite clinical efficacy.

Supply chain vulnerabilities, including raw material shortages from China and India, threaten production continuity. Geopolitical tensions further complicate cost structures, reducing margins during the Celecoxib market growth forecast period.

Market Segmentation

Loading chart…

Application is a critical axis of Celecoxib segmentation, with distinct therapeutic use-cases driving market demand. The primary application is Arthritis Management, accounting for ~62% of the market, driven by chronic rheumatoid arthritis and osteoarthritis treatment. This segment thrives on long-term prescriptions, supported by COX-2 inhibitor efficacy in reducing inflammation. A secondary application, Pain Management, contributes ~38%, addressing acute post-surgical or musculoskeletal pain. This segment benefits from over-the-counter availability in some regions, though prescription dominance persists. Together, these applications reflect the drug’s dual role in chronic and acute care, shaping market taxonomy through healthcare provider preferences and patient adherence rates.

Types of Celecoxib formulations further refine the market taxonomy, with Capsules and Tablets as dominant subtypes. Capsules (45% market share) are preferred for sustained-release formulations, ideal for chronic arthritis patients requiring consistent dosing. Their ease of swallowing and reduced gastrointestinal irritation enhance patient compliance. Tablets (55% share) dominate short-term pain relief due to immediate-release profiles and lower production costs. Regional preferences and regulatory approvals also influence this segmentation; for instance, tablets are more prevalent in emerging markets due to cost efficiency. These subtypes collectively define market dynamics, with innovation in capsule formulations driving incremental growth while tablets maintain volume-based dominance.

Celecoxib Segmentation Breakdown11 items

Application

Rheumatoid arthritis

osteoarthritis

Acute pain

Musculoskeletal pain

Other diseases

Types

50mg

100mg

200mg

400mg

Regional Insights

Loading chart…

The North America region dominates the Celecoxib market with a 40% share, driven by high adoption of advanced therapeutics, robust R&D investments, and a mature healthcare ecosystem. Regulatory policies prioritizing patient safety and innovation further accelerate market growth. Meanwhile, Asia Pacific emerges as the fastest-growing region, fueled by rising chronic disease prevalence, expanding healthcare infrastructure, and government initiatives to improve pharmaceutical accessibility. These dynamics position the region for a 10% CAGR in the regional forecast.

Regional Growth Drivers5 items

North America: Advanced healthcare infrastructure, high R&D investments, and strong patient adoption of FDA-approved therapies.

Europe: Stringent regulatory frameworks ensuring drug safety and a well-established pharmaceutical ecosystem with high treatment adherence.

Asia Pacific: Urbanization-driven healthcare demand, increasing middle-class affordability, and growing partnerships between global and local drug manufacturers.

Latin America: Emerging healthcare reforms and rising awareness of non-steroidal anti-inflammatory drugs (NSAIDs) for arthritis management.

Middle East & Africa: Government-led healthcare modernization projects and expanding access to affordable generic Celecoxib formulations.

The Celecoxib market growth trajectory underscores North America as the largest market, while Asia Pacific leads in expansion potential. Strategic investments in ecosystem maturity and policy alignment will be critical to capitalize on regional forecast opportunities.

Competitive Landscape

The Celecoxib competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players. Key competitive dynamics are shaped by pricing strategies, regulatory approvals, and distribution networks. Global entities like Pfizer Inc. and Teva dominate through established commercialization infrastructure, while regional actors such as Lupin and Hengrui Medicine leverage localized manufacturing and cost advantages. Certification standards and compliance with evolving pharmacovigilance norms further influence market positioning. Pricing remains a critical lever, with manufacturers balancing generic market pressures against branded formulations.

Strategic differentiation in the Celecoxib market centers on R&D investments, supply chain resilience, and market access initiatives. Companies pursue partnerships for API sourcing, expand into emerging markets through joint ventures, or optimize formulations to address bioavailability challenges. A notable challenge is compliance costs, driven by stringent FDA and EMA guidelines. Competitive positioning also hinges on portfolio breadth, with firms like Mylan and Apotex emphasizing multi-product offerings to capture diverse therapeutic segments.

Pfizer Inc. focuses on regional expansion through partnerships in Asia-Pacific markets.

Teva prioritizes vertical integration to control API production costs and ensure supply stability.

Mylan emphasizes premium pricing for its Celecoxib branded variants in developed markets.

Apotex leverages local manufacturing to reduce lead times in Latin American and African regions.

Lupin adopts OEM tie-ups to expand its generic drug distribution footprint in Europe.

Hengrui Medicine invests in innovation pipeline to develop next-generation NSAID combinations.

Key Celecoxib Companies6 items

Pfizer Inc.

Teva

Mylan

Apotex

Lupin

Hengrui Medicine

Market Ecosystem

The Celecoxib ecosystem spans upstream raw material suppliers, midstream pharmaceutical manufacturers, and downstream distribution networks. Value is generated through R&D-driven formulation, regulatory compliance, and targeted delivery to therapeutic end markets. The ecosystem reflects interdependencies between input quality, production standards, and healthcare system dynamics.

Raw material suppliers — provide APIs, excipients, and packaging components for Celecoxib production

API manufacturers — synthesize celecoxib active pharmaceutical ingredient (API) under GMP standards

Pharmaceutical manufacturers — formulate, package, and brand Celecoxib as final-dose products

Technology providers — supply formulation equipment and quality control systems for production

Distributors — manage logistics of Celecoxib to pharmacies, hospitals, and specialty clinics

Healthcare providers — prescribe Celecoxib for arthritis and pain management per clinical guidelines

Regulatory bodies — enforce safety standards and approve Celecoxib formulations for market access

Control points reside with regulatory agencies governing approvals and patent holders influencing formulation innovations. Dependency risks include API supply chain constraints and evolving compliance requirements. Switching costs between manufacturers are moderate due to regulatory dossier requirements, while interoperability challenges arise in multi-vendor distribution networks. Regional variations in healthcare reimbursement policies further shape ecosystem dynamics.

Recent Industry Insights

The Celecoxib industry trends over the past 18 months reflect a dynamic landscape shaped by strategic collaborations, regulatory shifts, and evolving market demands. Key developments include the expansion of partnerships between pharmaceutical firms and contract manufacturers to enhance supply chain efficiency and meet growing global demand for generic Celecoxib formulations. Notably, a major player in the non-steroidal anti-inflammatory drug (NSAID) space acquired a mid-sized biotech firm in 2023, strengthening its intellectual property portfolio and accelerating R&D in NSAID-based therapies. Meanwhile, regulatory updates from the FDA in late 2023 emphasizing stricter labeling requirements for NSAIDs have prompted manufacturers to revise packaging and patient education materials. Consumer preferences are also shifting toward safer NSAID alternatives, with Celecoxib maintaining a competitive edge due to its cardiovascular risk profile compared to traditional NSAIDs. Additionally, funding rounds in 2024 have fueled innovations in extended-release formulations, targeting chronic pain management markets. Looking ahead, industry participants are prioritizing cost-effective manufacturing and digital health integrations to align with enterprise trends in precision medicine.

Analyst Overview

The Celecoxib market outlook remains cautiously optimistic, driven by its established role in managing chronic inflammatory conditions and arthritis. Market attractiveness is underscored by growing geriatric populations and rising prevalence of musculoskeletal disorders, though patent expirations in key regions temper growth potential. Competitive intensity is moderate, with a mix of branded innovators and generic manufacturers vying for market share, while pricing pressures and regulatory scrutiny shape strategic dynamics.

Long-term outlook hinges on therapeutic innovation and expanded indications, though incremental advancements rather than disruptive breakthroughs are anticipated. The innovation landscape is fragmented, with limited pipeline candidates focusing on enhanced drug delivery systems. Demand–supply balance remains stable, supported by consistent production capacity, but raw material volatility poses localized risks. Key risk factors include stringent regulatory requirements, biosimilar competition, and potential safety concerns necessitating post-marketing surveillance.

12 items

1. Executive Summary

2. Celecoxib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Celecoxib Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Celecoxib Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Celecoxib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Celecoxib Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Celecoxib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Celecoxib Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Celecoxib Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Celecoxib Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Celecoxib Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Celecoxib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Celecoxib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Celecoxib Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Celecoxib Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Celecoxib Market Competition by Key Manufacturers

9.1. Global Celecoxib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Celecoxib: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Pfizer Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Teva

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Mylan

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Apotex

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Lupin

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Hengrui Medicine

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Celecoxib Market

Figure 4: Global Celecoxib Market: Drivers

Figure 5: Global Celecoxib Market: Challenges

Figure 6: Global Celecoxib Market: Trends

Figure 7: Global Celecoxib Market: Opportunity

Figure 8: Global Celecoxib Market: Restraint

Figure 9: Global Celecoxib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Celecoxib Market Value (USD Million) By Region

Figure 19: Global Celecoxib Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Celecoxib Market Value (USD Million) By Region

Figure 27: Global Celecoxib Market Share (%) By: Regions (2032)

Figure 28: Global Celecoxib Market Volume (K) By Region

Figure 29: Global Celecoxib Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Celecoxib Market Value (USD Million) By Region

Figure 37: Global Celecoxib Market Share (%) By: Regions (2032)

Figure 38: Global Celecoxib Market Volume (K) By Region

Figure 39: Global Celecoxib Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Celecoxib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Celecoxib Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Celecoxib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Celecoxib Market Value (USD Million) By Region

Table 14: Global Celecoxib Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Celecoxib Market Volume (K) By Region

Table 31: Global Celecoxib Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Celecoxib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Celecoxib Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Celecoxib Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Pfizer Inc. Basic Information And Sales Area

Table 52: Pfizer Inc.. Products Portfolio

Table 53: Teva Basic Information And Sales Area

Table 54: Teva. Products Portfolio

Table 55: Mylan Basic Information And Sales Area

Table 56: Mylan. Products Portfolio

Table 57: Apotex Basic Information And Sales Area

Table 58: Apotex. Products Portfolio

Table 59: Lupin Basic Information And Sales Area

Table 60: Lupin. Products Portfolio

Table 61: Hengrui Medicine Basic Information And Sales Area

Table 62: Hengrui Medicine. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Celecoxib Market Value (USD Million) By Region

Table 72: Global Celecoxib Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Celecoxib Market Volume (K) By Region

Table 89: Global Celecoxib Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Celecoxib Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.71 billion
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Teva; Mylan; Apotex; Lupin; Hengrui Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Celecoxib Segmentation Breakdown11 items

Application

Rheumatoid arthritis

osteoarthritis

Acute pain

Musculoskeletal pain

Other diseases

Types

50mg

100mg

200mg

400mg

Regional Insights

Loading chart…

Regional Growth Drivers5 items

North America: Advanced healthcare infrastructure, high R&D investments, and strong patient adoption of FDA-approved therapies.

Europe: Stringent regulatory frameworks ensuring drug safety and a well-established pharmaceutical ecosystem with high treatment adherence.

Asia Pacific: Urbanization-driven healthcare demand, increasing middle-class affordability, and growing partnerships between global and local drug manufacturers.

Latin America: Emerging healthcare reforms and rising awareness of non-steroidal anti-inflammatory drugs (NSAIDs) for arthritis management.

Middle East & Africa: Government-led healthcare modernization projects and expanding access to affordable generic Celecoxib formulations.

Competitive Landscape

Pfizer Inc. focuses on regional expansion through partnerships in Asia-Pacific markets.

Teva prioritizes vertical integration to control API production costs and ensure supply stability.

Mylan emphasizes premium pricing for its Celecoxib branded variants in developed markets.

Apotex leverages local manufacturing to reduce lead times in Latin American and African regions.

Lupin adopts OEM tie-ups to expand its generic drug distribution footprint in Europe.

Hengrui Medicine invests in innovation pipeline to develop next-generation NSAID combinations.

Key Celecoxib Companies6 items

Pfizer Inc.

Teva

Mylan

Apotex

Lupin

Hengrui Medicine

Market Ecosystem

Raw material suppliers — provide APIs, excipients, and packaging components for Celecoxib production

API manufacturers — synthesize celecoxib active pharmaceutical ingredient (API) under GMP standards

Pharmaceutical manufacturers — formulate, package, and brand Celecoxib as final-dose products

Technology providers — supply formulation equipment and quality control systems for production

Distributors — manage logistics of Celecoxib to pharmacies, hospitals, and specialty clinics

Healthcare providers — prescribe Celecoxib for arthritis and pain management per clinical guidelines

Regulatory bodies — enforce safety standards and approve Celecoxib formulations for market access

Recent Industry Insights

Analyst Overview

Table of Contents